They most commonly occur in patients with lung adenocarcinoma; HER2 mutations and amplifications have been reported in 1–4% and 2–5% of patients with lung adenocarcinoma, respectively [25,32,34,39,40]. This evidence concerns the gene ERBB2 and lung adenocarcinoma.